Cargando…

Polygenic risk-tailored screening for prostate cancer: A benefit–harm and cost-effectiveness modelling study

BACKGROUND: The United States Preventive Services Task Force supports individualised decision-making for prostate-specific antigen (PSA)-based screening in men aged 55–69. Knowing how the potential benefits and harms of screening vary by an individual’s risk of developing prostate cancer could infor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Callender, Tom, Emberton, Mark, Morris, Steve, Eeles, Ros, Kote-Jarai, Zsofia, Pharoah, Paul D. P., Pashayan, Nora
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6924639/ https://www.ncbi.nlm.nih.gov/pubmed/31860675 http://dx.doi.org/10.1371/journal.pmed.1002998

Ejemplares similares

Benefit, Harm, and Cost-effectiveness Associated With Magnetic Resonance Imaging Before Biopsy in Age-based and Risk-stratified Screening for Prostate Cancer
por: Callender, Thomas, et al.
Publicado: (2021)

Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosis
por: Pashayan, Nora, et al.
Publicado: (2015)

Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer: A Life-Table Model
por: Pashayan, Nora, et al.
Publicado: (2018)

Polygenic susceptibility to prostate and breast cancer: implications for personalised screening
por: Pashayan, N, et al.
Publicado: (2011)

Identification of Germline Genetic Variants that Increase Prostate Cancer Risk and Influence Development of Aggressive Disease
por: Saunders, Edward J., et al.
Publicado: (2021)

Germline genetic variation in prostate susceptibility does not predict outcomes in the chemoprevention trials PCPT and SELECT
por: Ahmed, Mahbubl, et al.
Publicado: (2019)

Reducing overdiagnosis by polygenic risk-stratified screening: findings from the Finnish section of the ERSPC
por: Pashayan, Nora, et al.
Publicado: (2015)

Prostate cancer risk in men of differing genetic ancestry and approaches to disease screening and management in these groups
por: McHugh, Jana, et al.
Publicado: (2021)

LocusExplorer: a user-friendly tool for integrated visualization of human genetic association data and biological annotations
por: Dadaev, Tokhir, et al.
Publicado: (2016)

BRCA1, BRCA2 and their possible function in DNA damage response
por: Kote-Jarai, Z, et al.
Publicado: (1999)

The effect of sample size on polygenic hazard models for prostate cancer
por: Karunamuni, Roshan A., et al.
Publicado: (2020)

Large-scale transcriptome-wide association study identifies new prostate cancer risk regions
por: Mancuso, Nicholas, et al.
Publicado: (2018)

Author Correction: Large-scale transcriptome-wide association study identifies new prostate cancer risk regions
por: Mancuso, Nicholas, et al.
Publicado: (2019)

Diffusion-weighted MRI for detecting prostate tumour in men at increased genetic risk
por: deSouza, Nandita M., et al.
Publicado: (2014)

Impact of germline DNA repair gene variants on prognosis and treatment of men with advanced prostate cancer
por: Hansen, Emma B., et al.
Publicado: (2023)

Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts
por: Seibert, Tyler M, et al.
Publicado: (2018)

Cost effectiveness of the NHS breast screening programme: life table model
por: Pharoah, Paul D P, et al.
Publicado: (2013)

Do cancer risk and benefit–harm ratios influence women’s consideration of risk-reducing mastectomy? A scenario-based experiment in five European countries
por: Rebitschek, Felix G., et al.
Publicado: (2019)

Incorporating genomics into breast and prostate cancer screening: assessing the implications
por: Chowdhury, Susmita, et al.
Publicado: (2013)

Validation of loci at 2q14.2 and 15q21.3 as risk factors for testicular cancer
por: Loveday, Chey, et al.
Publicado: (2017)

Polygenic hazard score is associated with prostate cancer in multi-ethnic populations
por: Huynh-Le, Minh-Phuong, et al.
Publicado: (2021)

Cost effectiveness analysis of a polygenic risk tailored breast cancer screening programme in Singapore
por: Wong, Jerry Zeng Yang, et al.
Publicado: (2021)

Potential of polygenic risk scores for improving population estimates of women’s breast cancer genetic risks
por: Wolfson, Michael, et al.
Publicado: (2021)

Relationship of self-reported body size and shape with risk for prostate cancer: A UK case-control study
por: Aladwani, Mohammad, et al.
Publicado: (2020)

Risk-Stratified Breast Cancer Screening Incorporating a Polygenic Risk Score: A Survey of UK General Practitioners’ Knowledge and Attitudes
por: Ayoub, Aya, et al.
Publicado: (2023)

Rare germline variants in DNA repair genes and the angiogenesis pathway predispose prostate cancer patients to develop metastatic disease
por: Mijuskovic, Martina, et al.
Publicado: (2018)

Correction: Rare germline variants in DNA repair genes and the angiogenesis pathway predispose prostate cancer patients to develop metastatic disease
por: Mijuskovic, Martina, et al.
Publicado: (2019)

CanRisk-Prostate: A Comprehensive, Externally Validated Risk Model for the Prediction of Future Prostate Cancer
por: Nyberg, Tommy, et al.
Publicado: (2023)

Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype
por: Mitra, A, et al.
Publicado: (2008)

Gene promoter hypermethylation in ductal lavage fluid from healthy BRCA gene mutation carriers and mutation-negative controls
por: Locke, Imogen, et al.
Publicado: (2007)

Height, selected genetic markers and prostate cancer risk: results from the PRACTICAL consortium
por: Lophatananon, Artitaya, et al.
Publicado: (2018)

Height, selected genetic markers and prostate cancer risk: results from the PRACTICAL consortium
por: Lophatananon, Artitaya, et al.
Publicado: (2017)

Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score
por: Huynh-Le, Minh-Phuong, et al.
Publicado: (2022)

Glutathione-S-transferase M1, T1 and P1 polymorphisms, and breast cancer risk, in BRCA1/2 mutation carriers
por: Kadouri, L, et al.
Publicado: (2008)

Homeobox B13 G84E Mutation and Prostate Cancer Risk
por: Nyberg, Tommy, et al.
Publicado: (2019)

Comprehensive Functional Annotation of 77 Prostate Cancer Risk Loci
por: Hazelett, Dennis J., et al.
Publicado: (2014)

Assessment of harms, benefits, and cost‐effectiveness of prostate cancer screening: A micro‐simulation study of 230 scenarios
por: Getaneh, Abraham M., et al.
Publicado: (2020)

Common genetic variants associated with disease from genome-wide association studies are mutually exclusive in prostate cancer and rheumatoid arthritis
por: Orozco, Gisela, et al.
Publicado: (2013)

BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients
por: Kote-Jarai, Z, et al.
Publicado: (2011)

A single-nucleotide polymorphism in the RAD51 gene modifies breast cancer risk in BRCA2 carriers, but not in BRCA1 carriers or noncarriers
por: Kadouri, L, et al.
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_r8bog6kq3mefokc5s0ipggre0q